“Our desire to increase our own knowledge of existing medicines drives innovation and leads to improved treatments for our patients.”
Chikai Lai, Director of Commercial Operations
Quality of Life
We believe that the patient should come first, so we’re working with renowned partners and universities to reimagine how drugs can benefit patients. Improving drugs means improving patients’ quality of life at every stage.
We ensure that decades of academic studies are translated into clinical research and product innovation. Working with our academic partners, we are able to address unexplored ways to improve patients’ conditions.
A NEW ERA OF CHOICE
Launched in 2016, NITYR™ (nitisinone) is our first commercial product and demonstrates the commitment we have to improving patients’ lives. NITYR contains the same nitisinone medication that Tyrosinaemia type 1 (HT-1) patients have always used, but has an improved formulation aiming to provide patients with greater convenience.
NITYR™ is a registered trademark of Cycle Pharmaceuticals Limited in the United Kingdom.
CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada
Are you a Professional willing to know more about Cycle’s products?